First data from the pilot trial, which involved 2500 women, were released in March. Eligibility determined In the IBIS program at the initial assessment, breast cancer is excluded, then risk and eligibility is determined. Genetic testing is done selectively. Women may take hormone replacement therapy where indicated. The dose, type and duration of HRT is recorded.
Recruitment relates directly to awareness, particularly amongst GPs, women and surgeons.
This must include awareness of paternal relatives with breast cancer, and awareness of possible increased risk for patients' relatives when a woman with breast cancer is being seen. Enquiries are welcomed and can be directed to recruitment centres throughout Australia. Professor John Forbes is IBIS Study Chairman and head of surgical oncology at the Newcastle Mater Misericordiae Hospital. More information about the results of the North American trial, which were released in 1998, can be found on the National Cancer Institute site . The views or opinions stated in external resources which are links on this home page do not necessarily reflect those of the National Breast Cancer Centre.